BioLineRx (BLRX) Cash from Investing Activities (2013 - 2025)

BioLineRx's Cash from Investing Activities history runs 13 years deep, the most recent figure standing at -$337000.0 for Q4 2025.

• On a quarterly basis, Cash from Investing Activities fell 103.02% year-over-year to -$337000.0 in Q4 2025; TTM through Dec 2025 was -$8.5 million, a 129.09% decrease from a year earlier, with the FY2025 full-year figure at -$8.5 million, down 129.09% from the prior year.
• Cash from Investing Activities eased to -$337000.0 in Q4 2025 per BLRX's latest filing, from $3.7 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $16.7 million in Q1 2024 and bottomed at -$36.3 million in Q1 2021.
• The 5-year median for Cash from Investing Activities is $3.8 million (2022), against an average of -$597250.0.
• Biggest YoY gain for Cash from Investing Activities was 267.16% in 2022; the steepest drop was 37437.5% in 2022.
• Year by year, Cash from Investing Activities stood at $4.0 million in 2021, then fell by 3.4% to $3.9 million in 2022, then slumped by 628.09% to -$20.4 million in 2023, then soared by 154.7% to $11.2 million in 2024, then slumped by 103.02% to -$337000.0 in 2025.
• Per Business Quant, the three latest BLRX Cash from Investing Activities figures stand at -$337000.0 (Q4 2025), $3.7 million (Q3 2025), and -$3.7 million (Q2 2025).